TerraBioGen LCFX Improves Plant Nutrient Efficiency


VANCOUVER, BRITISH COLUMBIA--(Marketwired - Feb. 2, 2016) - TerraBioGen Technologies Inc., a developer of proprietary high-value agriculturally bioactive products, announces the results of a recently completed study by the University of Guelph which demonstrated that TerraBioGen LCFX treatment provides statistically significant improvement in plant nutrient efficiency.

The study, conducted by Dr. Steven Rothstein's lab at the University of Guelph, consisted of corn plants grown hydroponically with either full nutrients (FN), low nutrients (LN) or low nutrients with LCFX treatment (LN+LCFX). The LCFX treated plants had a significant increase in shoot height and biomass, along with increased root diameter and surface area. LCFX treatment in LN plants had a significant increase in shoot nitrate levels compared to the LN plants suggesting increased nitrate uptake efficiency. In addition, the LCFX treated plants also contained significant increased concentrations of: chlorophyll (apical and basal leaf regions), plant starch, sucrose, and amino acids.

"We are impressed and pleased with the quality of the work conducted by Dr. Rothstein's lab in the completion of this study," said TerraBioGen's CEO, Blair Heffelfinger. "It suggests a strong link between improved nutrient efficiency and the yield improvements that we have seen in our field trials conducted with TerraBioGen LCFX."

About TerraBioGen

TerraBioGen Technologies Inc. is a developer of innovative, proprietary, high-value, environmentally sustainable bioproducts and biostimulants that improve crop health and yields, and increase abiotic and biotic stress tolerance in agricultural and horticultural crops. The Company is committed to research and development to continue to improve the effectiveness of its technologies, the quality of its products, and the creation of new product lines. Further, the Company is taking steps to secure intellectual property rights to these bioproducts and to formulate them in order to fully commercialize their potential.

This news release contains certain statements that may be deemed "forward-looking" statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although TerraBioGen believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Forward looking statements are based on the beliefs, estimates and opinions of TerraBioGen's management on the date the statements are made. Except as required by law, TerraBioGen undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

Contact Information:

Blair Heffelfinger
President & CEO
TerraBioGen Technologies Inc.
(604) 444-1023 ext 316
(604) 444-1043 (FAX)
bheffelfinger@terrabiogen.com

Bob Nowell
CFO & Corporate Secretary
TerraBioGen Technologies Inc.
(604) 444-1023 ext 306
(604) 444-1043 (FAX)
bnowell@terrabiogen.com